Latest Interviews
Showing 31–36 of 36 transcripts.
Clear all filters- All-In Podcast1h 29m
E108: Doxing debate, Nuclear fusion breakthrough, state of the markets & more
Jason, Sacks, Chamath, Calacanis, Friedberg, Cernovich, Sachs, Freeburg, Jay Cal, Jake, Draymond, Dave Chappelle, Chris Rock, Steph Curry, Joe Lacombe, Phil Helmuth, Bill Gates, Mark Andreessen, Sam Altman, Chris Dixon, Nick
Elon Musk announced a new policy banning persistent real-time location tracking of individuals to prevent stalking, while experts debated the balance between personal safety and free speech amidst his broader moderation challenges. Simultaneously, scientists at the National Ignition Facility achieved a historic net energy gain in nuclear fusion, sparking discussions on commercialization timelines and the economic viability of fusion versus solar power. In the financial sector, a stark correction in private equity and venture capital valuations is reshaping startup strategies, with firms pivoting toward capital efficiency and private equity acquisitions as public market multiples collapse.
- All-In Podcast1h 25m
E99: Cheating scandals, Twitter updates, rapid AI advancements, Biden's pardon, Section 230 & more
Biden, Chamath, Calacanis, Friedberg, Nick, Sax, David Sacks, J Cal, Phil Helmuth, Jason
Hosts conclude their 99-episode run while addressing production overloads, a surge in cross-industry cheating scandals, and Elon Musk's strained acquisition of Twitter amidst complex financial hurdles. The panel further analyzes Tesla's AI robotics advancements, President Biden's cannabis pardons, and the Supreme Court's upcoming review of Section 230 liability as experts debate free speech frameworks. Key announcements include the upcoming "All In Meetups" in Zurich and Miami, a high-stakes poker tournament featuring Chamath Palihapitiya, and the revelation that Jason Calacanis coined the title "Data Scientist" in 2008.
- All-In Podcast1h 25m
E97: SPAC updates, public/private market overview, Putin's end game & more
Putin, Chamath, Calacanis, Friedberg, Jake, Nick, David, Jason, Sacks
Chamath Palihapitiya announced the liquidation of his IPOD and IPOF SPACs to return capital to investors, citing an unsustainable market environment where valuation gaps and volatility have frozen exits for late-stage private companies. He forecast a catastrophic "washout" for the broader SPAC sector while criticizing systemic failures in venture capital diligence and ESG frameworks that obscure financial reality. The discussion further addressed looming geopolitical risks, including escalation in Ukraine and protests in Iran, arguing that institutional decay and demographic shifts are driving instability that requires a nuanced diplomatic approach rather than intervention.
- Goldman Sachs12 min
Investing Insights from Big Data
Goldman Sachs utilizes machine learning and natural language processing to ingest unstructured alternative data, such as credit card transactions and geolocation metrics, for investment strategies that supplement traditional financial analysis. The firm specifically addresses pandemic-driven market volatility by constructing a quantitative "COVID basket" that evaluates revenue exposure, supply chains, and industry classifications to neutralize sector-specific risks. This approach leverages real-time indicators to forecast shifts in high-impact sectors like home improvement and digital entertainment while mitigating exposure in travel and leisure industries.
- Milken Institute1h 1m
Is There Mojo in M&A?
Robert Rankin, Jonathan Coslet, DA, Ray, Steven, Nick, Rosie Greer
A resurgence in global M&A volumes, projected to reach $3.5 trillion this year, is driven by robust financing liquidity and a strategic shift by corporate boards from balance sheet repair to growth-focused acquisitions. While Private Equity participation remains normalized at 5% of total volume, heavy consolidation is occurring in pharmaceuticals, banking, and real estate sectors as firms navigate regulatory constraints and activist investor pressures. This market activity is further shaped by a bifurcated cost of capital that favors investment-grade borrowers and small private credit funds, forcing large deals to rely on alternative capital structures.
- Milken Institute58 min
The Role of Universities in Accelerating Bioscience Research
David Baltimore, Joel Burdick, James Economou, Michael Quick, Owen Witte, Stephen Mayo, Steve Mayo, Nick, Francis Collins, Remy, Joe Boistak, Charles, Eric Green, Ray Deshaies
A consortium of leading academic figures, including Nobel Laureate David Baltimore and experts from Caltech, UCLA, and USC, convened to evaluate the intersection of biological engineering and clinical translation in the face of funding constraints. The panel detailed successful strategies for "engineered immunity" projects, such as converting muscle cells into antibody producers and conducting early-stage human trials within university settings, while highlighting the critical need for interdisciplinary programs that bridge the gap between engineering PhDs and MDs. Despite progress, participants identified a persistent "valley of death" in early-stage financing and urged a cultural shift toward professional management and team-based funding mechanisms to sustain innovation.